Pan, Kelsey
Concannon, Kyle http://orcid.org/0000-0001-8445-6328
Li, Jing
Zhang, Jianjun
Heymach, John V.
Le, Xiuning http://orcid.org/0000-0002-8554-1185
Article History
Accepted: 21 July 2023
First Online: 17 August 2023
Competing interests
: J.Z. has acted as a consultant and/or adviser of AstraZeneca, Bristol Myers Squibb, GenePlus, Innovent, Johnson & Johnson and Novartis, and has received research grants from Johnson & Johnson, Merck and Novartis. J.V.H. has acted as an adviser of AstraZeneca, Boehringer Ingelheim, BrightPath Biotherapeutics, Bristol Myers Squibb, Catalyst Biotech, EMD Serono, Foundation Medicine, Genentech/Roche, GlaxoSmithKline, Guardant Health, Hengrui Pharmaceutical, Janssen, Kairos Ventures, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche, Sanofi/Aventis, Spectrum Pharmaceuticals and Takeda, has received research funding from AstraZeneca, GlaxoSmithKline and Spectrum, is included in a licensing agreement between Spectrum and MD Anderson Cancer Center regarding intellectual property relating to treatments targeting of EGFR and HER2 exon 20 mutations, and declares stock and other ownership interests in Bio-Tree Consulting and Cardinal Spine. X.L. has acted as a consultant and/or adviser of Abbvie, AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Eli Lilly, EMD Serono (Merck KGaA), Hengrui Therapeutics, Janssen, Novartis, Sensei Biotherapeutics and Spectrum Pharmaceutics, and has received research funding from Boehringer Ingelheim, Eli Lilly, EMD Serono and Regeneron. The other authors declare no competing interests.